


1645



PATENT
ATTORNEY DOCKET NO.: UCSD1360-1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Albani et al. Art Unit: 1645
Application No.: 10/001,938 Examiner: Unassigned
Filed: October 31, 2001
Title: IMMUNOMODULATORY PEPTIDES DERIVED FROM HEAT SHOCK
PROTEINS AND USES THEREOF

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED

AUG 06 2003

TRANSMITTAL SHEET

TECH CENTER 1600/2900

Transmitted herewith for the above-identified application please find:

1. Information Disclosure Statement (2 pages);
2. Form PTO-1449 (1 page);
3. Four (4) Other Documents;
4. A copy of a Communication from a Foreign Patent office in a corresponding Foreign application mailed May 12, 2003 (11 pages); and
5. Return Receipt Postcard.

CERTIFICATION UNDER 37 CFR §1.8

I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on this date, July 29, 2003, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Cecilia Tobin

(Name of Person Mailing Paper)


(Signature)

Applicants: Albani et al.
Application No.: 10/001,938
Filed: October 31, 2001
Page 2

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement, because it is being filed prior to the receipt of a first office action on the merits of the above-captioned application. However, if any fee is required, authorization is hereby given to charge any other fees associated with the filings submitted herewith, or credit any overpayment to Deposit Account No. 50-1355. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Date: July 29, 2003



Lisa A. Haile, J.D., Ph.D.
Registration No. 38,347
Telephone: (858) 677-1456
Facsimile: (858) 677-1465

USPTO CUSTOMER NUMBER 28213
GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1100
San Diego, CA 92121-2133



PATENT
ATTORNEY DOCKET NO.: UCSD1360-1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Albani et al. Art Unit: 1645
Application No.: 10/001,938 Examiner: Unassigned
Filed: October 31, 2001
Title: IMMUNOMODULATORY PEPTIDES DERIVED FROM HEAT SHOCK
PROTEINS AND USES THEREOF

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED

AUG 06 2003


INFORMATION DISCLOSURE STATEMENT

TECH CENTER 1600/2900

Sir:

In accordance with 37 C.F.R. § 1.97, enclosed are references relating to the above-identified application. For the convenience of the Examiner, these references are listed on the attached Form PTO-1449 and copies are enclosed herewith.

It is respectfully requested that these references be considered in the examination of this application and their consideration be made of written record in the application file.

CERTIFICATION UNDER 37 CFR §1.8
I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on this date, July 29, 2003, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
Cecilia Tobin (Name of Person Mailing Paper)
 (Signature)

Applicants: Albani et al.
Application No.: 10/001,938
Filed: October 31, 2001
Page 2

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement, because it is being filed prior to the receipt of a first office action on the merits of the above-captioned application. However, if any fee is required, authorization is hereby given to charge any other fees associated with the filings submitted herewith, or credit any overpayment to Deposit Account No. 50-1355. A duplicate copy of this sheet is enclosed.

Respectfully submitted,


Date: July 29, 2003



Lisa A. Haile, J.D., Ph.D.
Registration No. 38,347
Telephone: (858) 677-1456
Facsimile: (858) 677-1465

USPTO CUSTOMER NUMBER 28213
GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1100
San Diego, CA 92121-2133

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Docket No.: UCSD1360-1	Application No.: 10/001,938
	Applicants: Albani et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date: October 31, 2001	Group Art Unit: 1645



RECEIVED

AUG 06 2003

U.S. PATENT DOCUMENTS

TECH CENTER 1600/2900

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	NONE					

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (YES/NO)
	NONE					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

AA	Albani et al., "Positive selection in autoimmunity: Abnormal immune response to a bacterial dnaJ antigenic determinant in patients with early rheumatoid arthritis," <i>NATURE MEDICINE</i> , 1 (5) :448-452
AB	McColl et al., "Absence of peripheral blood T cell responses to 'shared epitope' containing peptides in recent onset rheumatoid arthritis," <i>Analys Rheum Dis</i> , 56 :240-246 (1997)
AC	McSorely et al., "Selective tolerization of Th1-like cells after nasal administration of a cholera toxin-LACK conjugate," <i>Eur. J. Immunol.</i> , 28 :424-432 (1998)
AD	Vandenbark et al., "Differential susceptibility of human T _H 1 versus T _H 2 cells to induction of anergy and apoptosis by EDCI/antigen-coupled antigen-presenting cells," <i>International Immunology</i> , 12 (1) :57-66 (1999)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449

Gray Cary\GT\6358854.1

101668-62

PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

PCT

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL SEARCH REPORT
OR THE DECLARATION

(PCT Rule 44.1)

COPY

To:

GRAY CARY WARE & FREIDENRICH LLP
Attn. Haile, Lisa A.
4365 Executive Drive, Suite 1100
San Diego, California 92101-2133
UNITED STATES OF AMERICA

Date of mailing
(day/month/year)

12/05/2003

Applicant's or agent's file reference

UCSD1360WO

FOR FURTHER ACTION

See paragraphs 1 and 4 below

International application No.

PCT/US 01/ 45344

International filing date

(day/month/year)

31/10/2001

Applicant

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

1. ☒ The applicant is hereby notified that the International Search Report has been established and is transmitted herewith.

Filing of amendments and statement under Article 19:

The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):

When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.

Where? Directly to the International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland
Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2. ☐ The applicant is hereby notified that no International Search Report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3. ☐ **With regard to the protest** against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.

☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Further action(s):** The applicant is reminded of the following:

Shortly after **18 months** from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

Within **19 months** from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within **20 months** from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the International Searching Authority



European Patent Office, P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Stefanie Böhler
Stefanie Böhler

NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions, respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

1. [Where originally there were 48 claims and after amendment of some claims there are 51]:
"Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
2. [Where originally there were 15 claims and after amendment of all claims there are 11]:
"Claims 1 to 15 replaced by amended claims 1 to 11."
3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:
"Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or
"Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
4. [Where various kinds of amendments are made]:
"Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

"Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the international application is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments and any accompanying statement, under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the time of filing the amendments (and any statement) with the International Bureau, also file with the International Preliminary Examining Authority a copy of such amendments (and of any statement) and, where required, a translation of such amendments for the procedure before that Authority (see Rules 55.3(a) and 62.2, first sentence). For further information, see the Notes to the demand form (PCT/IPEA/401).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference UCSD1360WO	FOR FURTHER ACTION <small>see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.</small>	
International application No. PCT/US 01/ 45344	International filing date (day/month/year) 31/10/2001	(Earliest) Priority Date (day/month/year) 01/11/2000
Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 8 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☒ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☒ furnished subsequently to this Authority in computer readable form.

☒ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☒ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☒ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☐ the text is approved as submitted by the applicant.

☒ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☒ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

2
☐ None of the figures.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 01/45344

Box III TEXT OF THE ABSTRACT (Continuation of item 5 of the first sheet)

A method of modulating an immune response in a subject, the method comprising administering an immunogenic peptide portion of a dnaJ heat shock protein (hsp) to the subject, thereby modulating an immune response in the subject. The invention is based on the discovery that an effective therapeutic strategy for ameliorating the inflammation-related symptoms of an immune-mediated disease, such as arthritis, can be achieved by modulation of the underlying immune response itself, rather than by merely addressing the resulting inflammation. This strategy can be used to regulate the inflammatory response and is applicable to a variety of contexts in which immune modulation is desired, such as mucosal tolerization, DNA vaccination, anergy induction, active immunization, and ex vivo modulation of antigen-specific T cells. In one embodiment, the method comprises administering to the subject a bacterial dnaJ peptide or a human homolog or a non-homologous human isoform thereof.

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 14-24, 36-56
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.: 14-24, 36-56
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-5, 7-10, 13, 25-42, 45-73 (all partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 1-56 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Claims Nos.: 14-24, 36-56

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

Continuation of Box I.2

Claims Nos.: 14-24, 36-56

Present claims 14-24 relate to a method defined by reference to a desirable characteristic or property, namely "the peptide has a pro-inflammatory/anti-inflammatory response". An attempt is made to define the method by reference to a result to be achieved. Therefore, said claims lack clarity within the meaning of Art. 6 PCT. This lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the methods where the seq. id of the peptides (of invention 1, only) are mentioned, e.g. claim 4, 10 and 12.

Present claim 8 lacks clarity within the meaning of Article 6 PCT, since the terms "HSJ1, HDJ1 and HDJ2" are not clear.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-5,7-10,13,25-42,45-73 (all partial)

Bacterial dnaj peptide with seq. id no:1 and homologous human sequences with seq id no:9, 10, 11

2. Claims: 1-5,7-10,13,25-42,45-73 (all partial)

Bacterial dnaj peptide with the seq. id no:2 and homologous human sequences with the seq. id's 12, 13 and 14.

3. Claims: 1-4,13,25-38,45-73 (all partial)

Bacterial dnaj peptide with the seq. id no:3.

4. Claims: 1-5, 7-10,13,25-42,45-73 (all partial)

Bacterial dnaj peptide with seq. id no:4 and homologous human sequences with seq id no: 15, 16, 17

5. Claims: 1-4, 13,25-38,45-73 (all partial)

Bacterial dnaj peptide with the seq. id no:5.

6. Claims: 1-4, 13,25-38,45-73 (all partial)

Bacterial dnaj peptide with the seq. id no:6.

7. Claims: 1-4, 13,25-38,45-73 (all partial)

Bacterial dnaj peptide with the seq. id no:7.

8. Claims: 1-4, 13,25-38,45-73 (all partial)

Bacterial dnaj peptide with the seq. id no:8.

9. Claims: 1,5-9,11-13,25-36,39-40,43-73 (all partial)

Non-homologous human peptide with the seq. id 18 and seq. 19 (sharing sequence homology to each other).

10. Claims: 1,5-9,11-13,25-36,39-40,43-73 (all partial)

Non-homologous human peptide with the seq. id 20.

11. Claims: 1,5-9,11-13,25-36,39-40,43-73 (all partial)

Non-homologous human peptide with the seq. id 21.

12. Claims: 1,5-9,11-13,25-36,39-40,43-73 (all partial)

Non-homologous human peptide with the seq. id 22.

13. Claims: 1,5-9,11-13,25-36,39-40,43-73 (all partial)

Non-homologous human peptide with the seq. id 23.

14. Claims: 1,5-9,11-13,25-36,39-40,43-73 (all partial)

Non-homologous human peptide with the seq. id 24.

15. Claims: 1,5-9,11-13,25-36,39-40,43-73 (all partial)

Non-homologous human peptide with the seq. id 25.

16. Claims: 1,5-9,11-13,25-36,39-40,43-73 (all partial)

Non-homologous human peptide with the seq. id 26.

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K7/08 A61K38/10 C12N15/00 C12N15/11

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K A61K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ALBANI S ET AL: "POSITIVE SELECTION IN AUTOIMMUNITY: ABNORMAL IMMUNE RESPONSES TO A BACTERIAL DNAJ ANTIGENIC DETERMINANT IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS" NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 1, no. 5, 1 May 1995 (1995-05-01), pages 448-452, XP002033102 ISSN: 1078-8956 the whole document --- -/--	1-3, 13-37

☒ Further documents are listed in the continuation of box C.☐ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

19 December 2002

Date of mailing of the international search report

12.05.03

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Lüdemann, S

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>MCCOLL GEOFFREY J ET AL: "Absence of peripheral blood T cell responses to 'shaped epitope' containing peptides in recent onset rheumatoid arthritis." ANNALS OF THE RHEUMATIC DISEASES, vol. 56, no. 4, 1997, pages 240-246, XP009003103 ISSN: 0003-4967 the whole document</p>	1-3, 13-37